PHARMARON BEIJING CO., LTD. Pharmaron Beijing Co., Ltd. Stock Hong Kong S.E.
Equities
3759
CNE100003PG4
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.83 HKD | +2.50% |
|
-4.00% | -37.86% |
| Sales 2024 * | 12.65B 1.75B 13.66B 2.38B | Sales 2025 * | 15.24B 2.1B 16.46B 2.87B | Capitalization | 33.27B 4.59B 35.93B 6.26B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.61B 223M 1.74B 303M | Net income 2025 * | 2.16B 298M 2.33B 407M | EV / Sales 2024 * | 2.89 x |
| Net Debt 2024 * | 3.36B 464M 3.63B 632M | Net Debt 2025 * | 3.14B 433M 3.39B 590M | EV / Sales 2025 * | 2.39 x |
| P/E ratio 2024 * |
21
x | P/E ratio 2025 * |
17.5
x | Employees | - |
| Yield 2024 * |
1.04% | Yield 2025 * |
1.39% | Free-Float | 47.74% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.50% | ||
| 1 week | -4.00% | ||
| 1 month | +1.24% | ||
| 3 months | -6.02% | ||
| 6 months | -46.86% | ||
| Current year | -37.86% |
1 week
9.50
10.44
1 month
9.5012.02
Current year
8.2516.10
1 year
8.2523.40
3 years
8.2594.22
5 years
8.2594.22
10 years
8.2594.22
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Qiang Lou
FOU | Founder | 55 | 04-06-30 |
Bei Zheng
FOU | Founder | 57 | 04-06-30 |
Bo Liang Lou
CEO | Chief Executive Officer | 60 | 04-06-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kwan Hung Tsang
BRD | Director/Board Member | 60 | 19-08-14 |
Bo Liang Lou
CEO | Chief Executive Officer | 60 | 04-06-30 |
Xiao Qiang Lou
FOU | Founder | 55 | 04-06-30 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.55% | 4 M€ | -27.92% | ||
| 0.57% | 2 M€ | -18.79% | - | |
| 0.26% | 3 M€ | +0.10% | - | |
| 0.09% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 9.83 | +2.50% | 6,235,773 |
| 24-05-30 | 9.59 | -2.34% | 3,988,703 |
| 24-05-29 | 9.82 | -1.70% | 2,615,884 |
| 24-05-28 | 9.99 | -0.70% | 2,346,500 |
| 24-05-27 | 10.06 | -1.76% | 4,732,125 |
Delayed Quote Hong Kong S.E., May 31, 2024 at 04:08 am
More quotes
Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows:
- laboratory services (61.3%);
- development and production of chemical processes and formulations (23.5%);
- clinical research services (12.8%);
- other (2.4%);
Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).
Calendar
2024-06-06
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
20.64
CNY
Average target price
24.15
CNY
Spread / Average Target
+16.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- 300759 Stock
- 3759 Stock
